5-Level (EQ-5D-5L).

Safety Profile: Across both studies, oveporexton was generally well-tolerated. No treatment-related serious adverse events were observed. Consistent with our experience from previous clinical studies, the most common adverse events were insomnia, urinary urgency and frequency. Most adverse events were mild to moderate.


“We are leveraging our leadership in orexin science and development with the aim to bring oveporexton to patients expeditiously in partnership with health authorities,” said Sarah Sheikh, M.Sc., B.M., B.Ch., MRCP, Head, Neuroscience Therapeutic Area Unit and Global Development at Takeda. “We are excited to share these transformative results at World Sleep, which demonstrate the potential for a new era of care defined by multiple treatment measures that matter to patients.”

Takeda will share other presentations during the World Sleep Congress in oral and poster sessions, including the impact
=*=*=*=*=*=
当前为第6/18页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页